e-Drug3D 732 |
EPOPROSTENOL
|
cas 35121-78-9 |
CLASS BLOOD |
ROUTE (list) INJECTION |
ATC code |
PK parameters t1/2 0.1 HOUR |
Target - |
DrugCentral Prostaglandin E2 receptor EP1 subtype UNIPROT P34995 PTGER1 Prostacyclin receptor UNIPROT P43119 PTGIR |
Download SDF file | 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid Formula: Calculated chemical properties: MW 351.45 NB_atoms 25 XLogP 2.07 PSA 84.845 NB_HD 2 NB_HA 5 fsp3 0.75 Lipinski(0=no;1=yes) 1 |
FDA NDA 020444 (pdf not found) INN (EPOPROSTENOL SODIUM) FLOLAN (GLAXOSMITHKLINE LLC) APPROVAL= AP YEAR= 1995 NDA 022260 (pdf not found) INN (EPOPROSTENOL SODIUM) VELETRI (ACTELION) APPROVAL= AP YEAR= 2008 NDA 078396 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (MEITHEAL) APPROVAL= AP YEAR= 2008 NDA 210473 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (SUN PHARM) APPROVAL= AP YEAR= 2021 NDA 213913 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (MYLAN) APPROVAL= AP YEAR= 2024 NDA 219237 (pdf not found) INN (EPOPROSTENOL SODIUM) EPOPROSTENOL SODIUM (GLAND PHARMA LIMITED) APPROVAL= TA YEAR= 2025 |
Other links: |